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Abstract 
Development of a vaccine against herpes simplex virus (HSV) is an important goal for global sexual 
and reproductive health. In order to more precisely define the health and economic burden of HSV 
infection and the theoretical impact and cost-effectiveness of an HSV vaccine, in 2015 the World 
Health Organization convened an expert consultation meeting on HSV vaccine impact modelling. The 
experts reviewed existing model-based estimates and dynamic models of HSV infection to outline 
critical future modelling needs to inform development of a comprehensive business case and 
preferred product characteristics for an HSV vaccine. This article summarizes key findings and 
discussions from the meeting on modelling needs related to HSV burden, costs, and vaccine impact, 
essential data needs to carry out those models, and important model components and parameters. 
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Introduction 
In 2014, the World Health Organization (WHO), the National Institutes of Allergy and Infectious 
Diseases (NIAID), and global technical partners outlined a comprehensive roadmap for the 
development of effective new vaccines against sexually transmitted infections (STIs).1 The roadmap 
highlighted the urgent need for a vaccine against herpes simplex virus type 2 (HSV-2), because of the 
large numbers of HSV-2 infections globally, with more than 400 million infections estimated in 
2012,2 the fact that HSV-2 fuels the HIV epidemic by increasing the risk of HIV acquisition and 
transmission several-fold,3 and the limited population impact of current HSV prevention measures.4 
An HSV vaccine could have an impact not only on suffering due to genital ulcer disease (GUD), of 
which HSV-2 is the most common cause worldwide,5 but also on neonatal herpes, an uncommon but 
devastating condition, and potentially on the spread of HIV infection. Such a vaccine might also 
protect against HSV type 1 (HSV-1), which typically causes orolabial infection but has been 
increasingly implicated as a cause of genital herpes.6,7  
WHO and global partners are undertaking several activities to advance the global roadmap for STI 
vaccine development, and in particular, the critical need for an HSV vaccine.8 Preparations are 
underway to develop a global business case for HSV vaccines, to clearly articulate the public health 
need, global market, and anticipated pathway and costs for developing, licensing, and implementing 
an HSV vaccine, as well as the predicted cost-effectiveness and return on investment. The business 
case, sometimes referred to as the value proposition, is intended to support strategic planning and 
catalyse engagement and investment in HSV vaccine development, not only from innovators, 
vaccine manufacturers, and funders, but also from regulators, national decision-makers, and other 
key stakeholders across the public health spectrum. A complementary roadmap activity is 
generation of preferred product characteristics (PPCs) for HSV vaccines. PPCs reflect a formal WHO 
process to define and reach consensus on the desired characteristics of vaccines that would address 
priority public health and programmatic needs, particularly for low- and middle-income countries 
(LMICs).9 PPCs are intended to provide early guidance to product developers and policy makers to 
ensure that vaccine candidates will not only meet requirements for licensure, but more importantly 
that they will benefit LMICs and can be rapidly implemented following approval. 
Mathematical modelling can inform several critical areas of the business case for HSV vaccine and 
PPC development (Figure 1). The first step in generating a business case is to build a comprehensive 
picture of the public health burden of HSV infection, including the economic burden. Model-based 
estimates of the global and regional burden of HSV disease and its costs to society are necessary 
since global surveillance for these outcomes does not exist.2  The next step is to model the 
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theoretical population-level impact of an HSV vaccine on the disease and cost burden, in the context 
of other available inventions (e.g., anti-viral therapy). These models incorporate assumptions that 
are defined within PPCs, such as efficacy requirements, target population, and duration of 
protection. In turn, modelling can help clarify the range of vaccine characteristics that can maximize 
the vaccine’s public health impact and cost-effectiveness,10 to refine the ideal attributes defining 
PPCs and the target product profile used by vaccine developers (Fig 1). Target product profiles 
incorporate similar characteristics as the PPCs but may differ in that they typically also consider high-
income country (HIC) markets. Once the product profile is established, the vaccine development and 
licensing pathway, its associated risks and costs, and predicted revenue are considered in building a 
robust case for investment. 
In March 2015, WHO convened a two-day meeting of experts in HSV modelling, epidemiology, and 
health economics to outline critical modelling efforts needed to inform development of an HSV 
vaccine business case and PPCs: the WHO Consultation on HSV Vaccine Impact Modelling. The 
objectives of the meeting were 1) to review existing models and identify modelling needs related to: 
a) HSV infection and disease burden at global and regional levels, b) the costs of HSV infection and 
its sequelae, and c) the theoretical impact of an HSV vaccine; and 2) to outline key modelling 
activities to address the gaps, including prioritization of needed models on HSV burden, costs, and 
vaccine impact, determination of essential data needs to carry out those models, and guidance on 
important model components and parameters. This paper summarizes the main findings and 
discussions from the meeting. 
HSV natural history and vaccine development efforts 
HSV-1 and HSV-2 cause lifelong, incurable infections. After infecting skin or mucosa in the oral (HSV-
1) or genital (HSV-1 or HSV-2) area, HSV establishes persistent infection in neural ganglia. HSV can 
then intermittently travel back down nerve axons to cause either symptomatic genital or oral ulcers 
(often called a “recurrence”) or asymptomatic viral shedding.5 This process can occur repeatedly and 
frequently over a person’s lifespan. The majority of HSV infections are unrecognized or 
asymptomatic. Asymptomatic viral shedding occurs frequently, and most HSV transmission occurs in 
the absence of symptoms.11  
HSV-2 infection, which is sexually transmitted, is the leading cause of GUD globally. Regardless of 
whether an HSV-2 infection is symptomatic or asymptomatic, evidence suggests that it increases the 
risk of acquiring HIV infection by approximately 3-fold3 and can be transmitted to a neonate to cause 
neonatal herpes. Although neonatal herpes is rare, occurring in approximately 1 in 3000 to 1 in 
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12,000 live births,12-14 about 60% of infections are fatal if left untreated, and surviving infants may 
have long-term disabilities.15 HSV-2 is the most common cause of recurrent meningoencephalitis, 
and can also cause severe hepatitis and disseminated infection in immunocompromised people.5 
HSV-1 and HSV-2 share  >80% genetic homology of their protein-coding regions but have different 
clinical and epidemiologic features.16 HSV-1 typically causes orolabial infection, with clinical 
manifestations ranging from herpes labialis (“cold sores”) to gingivostomatitis and pharyngitis. Less 
common complications include sporadic encephalitis and keratitis.17 However, HSV-1 is now the 
leading cause of symptomatic first-episode genital herpes in some HIC settings, where infection in 
childhood has been decreasing.7 Genital HSV-1 infection has a milder natural history and is less likely 
to recur than HSV-2 infection.18 The virus types also have complex immunological interactions. For 
example, although HSV-1 infection does not appear to prevent acquisition of HSV-2, it does reduce 
the likelihood that acquired HSV-2 infection will be symptomatic.19 
Antiviral therapies for genital HSV infection can reduce the number of days with symptoms during 
recurrences and can be taken daily to reduce the frequency of recurrences. Within discordant 
relationships, use of antiviral therapy by the HSV-2 seropositive partner can decrease transmission 
by up to 50%.20 Condom use also partially decreases both HSV-2 acquisition and transmission.21  
However, neither of these approaches is used extensively enough to limit incidence or prevalence at 
the population level, and vaccines are likely the best option for effective HSV control.  
No licensed HSV vaccines currently exist, but a number of vaccine candidates are in various stages of 
preclinical and clinical development.22 These vaccines are primarily designed to prevent acquisition 
of HSV-2 infection before exposure (prophylactic) and/or to reduce symptoms and viral shedding 
among those with existing genital HSV-2 infection (therapeutic). The most advanced candidates to 
date have been recombinant glycoprotein subunit prophylactic vaccines, which have been studied in 
clinical trials in more than 20,000 people.6,23,24 In a trial in the late 1990s, an HSV glycoprotein D-2 
(gD2) vaccine reduced HSV-2 infection (by 40%) and disease (by 70%) among HSV-1 seronegative 
women, but not among men or HSV-1 seropositive women.24 However, in a follow-up trial among 
over 8000 HSV-1/HSV-2 seronegative women, the gD2 vaccine failed to prevent HSV-2 infection or 
disease.6 Interestingly, the vaccine did result in a significant decrease in HSV-1 infection (35% 
efficacy) and HSV-1-related genital disease (58% efficacy).  
In recent years, considerable focus has been placed on development of therapeutic vaccines.22 A 
recent Phase II trial showed a 65% decrease in both genital HSV-2 shedding frequency and days with 
genital lesions after the therapeutic vaccine series.25 All previous HSV vaccine trials, for both 
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prophylactic and therapeutic vaccines, have been conducted in HICs. A prophylactic vaccine is most 
needed in LMIC settings such as sub-Saharan Africa, where the prevalence and incidence of both 
HSV-2 and HIV are highest and where HSV-2 is thought to increase the risk of HIV infection, even in 
the absence of symptoms.2,3 The effect of a therapeutic vaccine on the risk of HIV acquisition among 
HSV-2-infected people remains unknown and could vary according to its immunologic mechanism 
and whether it may increase or decrease the presence of activated CD4+ T cells in the genital tract 
that are targets for HIV infection.26  
Model-based estimates of the burden of HSV infection and sequelae 
Meeting participants reviewed existing estimates of HSV infection and disease burden and identified 
critical gaps, needs and considerations. Key findings are summarized in Table 1. WHO estimated that 
417 million people aged 15–49 years had HSV-2 infection globally in 2012.2 The Global Burden of 
Disease (GBD) Study 2013 estimates were higher at over 1 billion HSV-2 infections worldwide, 
primarily because all ages were considered.27 Data used in both estimates were sparse in some 
regions. However, meeting participants generally agreed that current estimates were sufficient to 
inform the business case, but suggested comparison of WHO and GBD models, incorporation of data 
from high-risk populations, and exploration of additional data sources. The first global and regional 
estimates of HSV-1 infection were finalized after the meeting, estimating that 1.7 billion people aged 
0-49 years have HSV-1 infection and 140-280 million 15–49 year-olds have genital HSV-1 infection.28 
Prevalence estimates used to generate these projections were even sparser than for HSV-2, and 
meeting participants recommended evaluation of newer HSV-1 serological data where feasible and 
better data on the proportion of HSV-1 infections that are genital, especially in LMICs. 
Meeting participants identified more gaps related to HSV disease outcomes, such as GUD, neonatal 
herpes, and HSV-associated HIV infection. No detailed models estimating HSV-related GUD were 
identified. Meeting participants encouraged such a model, incorporating HSV-2 and HSV-1 natural 
history and available GUD surveillance data. The first global estimates of neonatal herpes were 
published after the meeting, and estimated that roughly 14,000 cases occurred annually during 
2010-2015 (10 cases per 100,000 livebirths).14 The estimates were based on HSV-1 and HSV-2 
prevalence and incidence estimates, pregnancy rates by region and age, and published risks of 
mother-to-child transmission by HSV type and stage from the United States.12 While these estimates 
are a good starting point to inform the business case, better primary data are needed on mother-to-
child HSV transmission risks and neonatal herpes incidence, especially in LMICs, to reduce 
uncertainty and refine future estimates. Several studies have evaluated the population attributable 
fraction of HIV due to HSV-2 infection in different settings.29-31 However, meeting participants agreed 
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that updated models, considering the degree to which incident HIV infections are attributable to 
HSV-2 and incorporating newer data on the HSV-HIV interaction, would be important to understand 
the potential impact of an HSV vaccine on HIV incidence under different epidemiologic scenarios, as 
outlined in Table 1. Additional reviews of HSV-1-related oral disease and other HSV-related 
outcomes, such as encephalitis, keratitis, and the psychosocial impact of HSV infection, would 
provide a more complete picture of the burden of HSV infection and the potential benefits of an HSV 
vaccine. 
Summary health measures such as quality-adjusted life years (QALYs), disability-adjusted life years 
(DALYs) and years lived with disability (YLDs) allow comparison of disease burden across multiple 
diseases and disease states. QALYs measure both life expectancy and the quality of remaining life-
years. The relative quality of life of a health state is often called the “QALY weight” or “health utility” 
(between 0 and 1; 0=death, 1=perfect health), which can be assessed with a range of available tools. 
YLDs measure the loss of health associated with a condition using a “disability weight,” and DALYs 
reflect YLDs plus years of potential life lost due to premature mortality. Although QALY weight 
estimates for adult HSV infection are limited, several tools exist to estimate the impact of HSV on 
quality of life, primarily incorporating the effect of symptoms but also including stigma and impact 
on relationships.32 QALY estimates for neonatal herpes are relatively more abundant in existing 
literature.33-35 Future needs include clarifying how to derive QALY estimates from existing quality of 
life scores, and obtaining quality of life data in LMICs.  The GBD study estimated that HSV-2 infection 
resulted in 311,600 YLDs in 2013 from GUD alone, using non-HSV-specific disability weights (e.g., 
“mild infection” for recurrences).27 The most severe disease outcomes, neonatal herpes and HSV-
associated HIV infection, were not included. Better data on these outcomes, their inclusion in 
YLD/DALY estimates, and improved disability weights, would considerably advance understanding of 
HSV burden.  
Model-based estimates of the economic burden of HSV infection and sequelae 
Model and data needs related to estimating the economic costs of HSV infection are summarized in 
Table 2. A few national estimates of the direct annual costs of diagnosing and treating HSV-2 
infection, and of the lifetime cost per case, exist for the United States. For example, in 2008 the 
annual direct cost of HSV-2 infection was estimated to be $541 million.36 One study has also 
estimated indirect costs of genital herpes (e.g., productivity losses due to absenteeism from work) at 
$214 million.37 These conservative estimates do not include costs of neonatal herpes nor HSV-
associated HIV. No such estimates have been found for other countries.  Although lifetime cost-per-
case estimates are limited, a wide range of itemized cost components are available for specific 
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procedures and conditions in HICs, e.g., costs related to HSV testing, counselling, suppressive 
therapy, and clinician visits.38 Meeting participants agreed that models to estimate aggregate annual 
and lifetime costs per case of HSV infection were needed outside the U.S., especially for LMICs. In 
addition, cost estimates incorporating neonatal herpes and HSV-associated HIV infection costs and 
updated data on HSV testing, antiviral use, and other factors would be important in all settings. To 
do this, it will be important to get better data on HSV care and treatment costs, healthcare seeking 
and testing practices for HSV disease, and utilization rates of HSV therapy including over-the-counter 
expenses and traditional medicine therapies in the informal sector, especially for LMICs. Use of 
administrative and health insurance claims data, and exploration of validated healthcare costs for 
related conditions in LMICs, were highlighted as potential avenues for gathering new data. 
No existing comprehensive cost estimates were found for HSV-1 infection, and meeting participants 
agreed that such estimates, incorporating current data on utilization of care and treatment for HSV-
1-related outcomes in both HICs and LMICs, would be valuable. Better information on HSV-1 disease 
occurrence and natural history will be useful, as will a review of oral HSV treatment and 
administration costs as they differ from genital HSV costs, e.g., topical treatment. Evaluation of 
administrative or claims data on oral HSV-1 evaluations and treatment could provide important 
information. 
Although costs of neonatal herpes and HSV-associated HIV infections have not been systematically 
included in aggregate cost estimates for HSV infection, estimates of the lifetime cost per case of 
these outcomes are available, as are itemized cost components. The estimated lifetime cost per case 
of neonatal herpes has been over $90,000 in the U.S. on average, but has ranged to much higher 
estimates depending on how long-term disability costs were included in models.38 The acute 
hospitalization cost per case has been estimated to be $40,044 alone.39 Several studies of the cost-
effectiveness of HSV screening and suppressive therapy in pregnant women (also in the U.S.) 
highlight the need to consider prevention costs, including Caesarean sections, in addition to the 
costs of treating neonatal herpes.40 Estimates of lifetime costs of HIV infection exist, though those 
costs have not been applied specifically to HSV-related HIV infection.41 In addition to inclusion of 
costs related to neonatal herpes and HSV-associated HIV infection, important needs include lifetime 
cost-per-case estimates for neonatal herpes in LMICs, and updated estimates using current data on 
neonatal herpes costs, clinical practice, and long-term disability as well as indirect cost estimates. 
Better data and estimates related to neonatal herpes incidence in LMICs and the attributable 
fraction of HIV due to HSV-2 infection will be critical in generating comprehensive HSV-related cost 
estimates. 
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Modelling efforts related to vaccine impact 
To determine key modelling needs to predict HSV vaccine impact, meeting participants discussed 
critical features such models would need to inform a comprehensive business case and PPCs. 
Dynamic models accounting for HSV transmission allow assessment of the potential impact of a 
vaccine in a population beyond the direct benefits to vaccinated individuals (i.e., account for herd 
immunity), and allow exploration of impact across different epidemiologic contexts.10,42 Such models 
can incorporate sexual contact patterns, the biology and natural history of the infection, 
susceptibility, transmissibility, interactions with other infections, and availability and characteristics 
of competing interventions, which can all vary across populations. Meeting participants discussed 
that there may be some limited utility for a simple static model, which assumes straightforward 
reductions in the per-person, age-specific incidence rates of HSV-related outcomes according to 
vaccine efficacy assumptions, to provide a high-level overview of the potential magnitude of costs 
and benefits of an HSV vaccine.43 However, it was emphasized that dynamic models are more 
appropriate to produce valid predictions of the theoretical impact of a vaccine in altering the natural 
history of the infection, interrupting HSV transmission, and reducing the population-wide incidence 
and prevalence of infection and disease. 
Critical questions for HSV vaccine impact modelling include: 
• Which populations and geographic/epidemiologic settings are considered? 
• Which type of vaccine, prophylactic or therapeutic, is modelled? 
• How is HSV-1 infection incorporated in the models? 
• Which disease outcomes are considered in the models? 
• How are vaccine characteristics modelled?  
• What are the most critical sensitivity and uncertainty analyses?  
• Are cost analyses incorporated into vaccine impact models? 
In preparation for the meeting, a literature review was conducted on existing mathematical models 
with relevance for assessing HSV vaccine impact. Thirty articles modelling dynamic HSV transmission 
were reviewed, including 8 articles directly modelling HSV vaccine impact.44-51 Overall, the HSV 
vaccine impact models predicted that even an imperfect HSV vaccine could have population benefits 
in terms of decreasing HSV prevalence and incidence; however, the models differed with respect to 
the predicted magnitude and timeframe required to achieve these benefits. A detailed summary and 
technical review of these models, including description of model structures, parameters and 
assumptions, outcomes, and how those factors affected results of the different models, can be 
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found in the review by Spicknall et al.52 The ability of existing models to inform the HSV vaccine 
business case and evaluate PPC parameters, as well as identification of key remaining modelling and 
data gaps, are discussed below in the context of the critical questions outlined above. 
Populations and/or geographic/epidemiologic settings 
Of the existing studies, four modelled HSV-2 vaccine impact in North America,46,47,50,51 two modelled 
impact in African settings,44,45 and two did not specify a setting.48,49 Baseline HSV-1 and HSV-2 
prevalence and incidence rates, sexual behaviour and networks, HIV prevalence, and vaccine 
delivery and healthcare costs can vary greatly across settings and can have a substantial impact on 
potential vaccine effectiveness and cost-effectiveness. Meeting participants felt it important to 
undertake dynamic modelling studies in at least three settings based on a combination of income 
status and HSV/HIV epidemiology: 1) a high income, low HIV prevalence setting (e.g., US, UK); 2) a 
low-income, high HSV/HIV prevalence setting (e.g., a sub-Saharan African country); and 3) a middle-
income, low to moderate HSV/HIV prevalence area (e.g., Brazil, China). Availability of good data on 
sexual behaviour, HSV and HIV prevalence and incidence, and transmission risks across subgroups 
will be important for all selected settings.  
Prophylactic versus therapeutic vaccine 
The main focus of existing modelling studies has been prophylactic vaccines; only one exclusively 
considered therapeutic vaccines.51 Prophylactic vaccines could also have disease-modifying effects 
for breakthrough infection, and this has been modelled previously.44-46,50 However, much of the 
recent research and development activity has been focused on therapeutic HSV vaccines. Meeting 
participants discussed the need for modelling both prophylactic and therapeutic vaccines. 
Considerations can differ for each, e.g., target population, with prophylactic vaccination targeted 
primarily before the onset of sexual debut, and therapeutic vaccination being given only to those 
who have recognized genital herpes infection. As such, the structure and costs of vaccine delivery 
differ between the vaccine types and also vary by setting. Another important consideration relates 
to the HSV-HIV association. Because HSV-2 infection increases the risk of HIV acquisition, even with 
no clinical disease, a prophylactic vaccine may be preferable in settings with high HIV prevalence. 
Nonetheless, reducing HSV disease and shedding episodes with a therapeutic vaccine might reduce 
HSV transmission in the population and reduce microscopic ulcerations that are portals of entry for 
HIV. However, theoretically if a vaccine induces activated CD4+ immune cells in the genital area as a 
mechanism of action, this might increase the number of target cells for HIV infection. Modelling 
analysis could vary vaccine-associated benefits and risks to explore the potential impact of a 
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therapeutic HSV vaccine on HIV infection. Data that can shed light on the mechanisms of action of 
new vaccine candidates would be extremely valuable.  
HSV shedding has been a key outcome in therapeutic vaccine trials (in addition to reduction in 
clinical recurrences). Thus, a better understanding of the association between reduction in shedding 
and translation to reduction in HSV transmission as well as susceptibility to HIV acquisition, is critical. 
Within-host models have attempted to predict transmission thresholds for HSV shedding, estimated 
to be around 104 DNA copies, but such models are difficult to validate clinically and uncertainty 
remains.53 
HSV-1 infection  
Two published HSV vaccine impact modelling studies only modelled vaccine delivery for HSV-1 
seronegative women, based on early gD2 vaccine trials.24,46,47 Other models have not explicitly 
considered HSV-1 infection. Meeting participants agreed that future models need to incorporate 
HSV-1 infection, in several respects. HSV-1 infection may be a potential target of vaccine action, may 
modify vaccine efficacy against HSV-2 infection, and may have other interactions with HSV-2. Ideally 
an HSV vaccine would prevent both HSV types, and the most recent Phase III trial of the gD2 vaccine 
showed a significant vaccine effect on HSV-1 infection.6 Including vaccine efficacy against HSV-1 
infection would broaden the range of HSV-associated outcomes that could be prevented with a 
vaccine and thus improve potential cost-effectiveness. It would also influence the target age at 
vaccination. HSV-2 vaccines have typically been designed with adolescents as the target population. 
However, the target group for an HSV-1 and -2 vaccine would likely be infants or children, especially 
in LMICs, where most people acquire HSV-1 infection prior to adolescence.28 If the vaccine is 
efficacious against HSV-2 infection only among HSV-1 seronegative people, this also has implications 
for target age of vaccination and costs of vaccine delivery. Dynamic models can also incorporate 
effects of prior HSV-1 infection on development of HSV-2 disease.  
Disease outcomes 
Most of the currently published dynamic models of potential HSV vaccine impact assessed only 
population HSV incidence and prevalence as the main disease outcomes, although one model 
assessed ongoing HIV transmission.45 Meeting participants agreed it will be important to have a 
comprehensive assessment of the potential impact of an HSV vaccine on the most important disease 
outcomes, including in particular neonatal herpes and HSV-associated HIV infections, as well as 
potential outcomes of HSV-1 infection. Critical to such efforts will be better data on the proportion 
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of HSV infections leading to these outcomes in different settings, and the associated QALYs or DALYs, 
as discussed above. 
Vaccine characteristics 
Meeting participants discussed several considerations related to how crucial vaccine characteristics 
are modelled. In terms of vaccine efficacy, the clinical endpoints modelled can affect predicted 
population outcomes: efficacy against infection, clinical disease, viral shedding, or a combination of 
these. Vaccine impact models can be useful in determining the most important clinical endpoints to 
measure in trials and how different endpoints affect efficacy outcomes. Another important 
consideration is how efficacy is modelled. For example, for a vaccine with presumed partial efficacy, 
a model can assume that only a fraction of people are fully protected (“take”-type protection) or 
that all people have protection against a fraction of exposures (“degree”-type protection), with 
varying results.42 Duration of protection provided by a vaccine is another key characteristic, though a 
firm estimate of duration requires long-term follow-up. Its impact may depend on the age at 
vaccination and how waning of protection is modelled. Important cost impact considerations include 
the number of doses and other factors affecting the cost of the vaccine and its delivery. 
Sensitivity and uncertainty analyses  
Sensitivity analysis involves varying key parameters in a model to determine their influence on 
model predictions. Uncertainty analysis involves using a range of plausible parameter values, which 
are identified after calibrating the model to selected epidemiological outcomes, to produce 
estimates that reflect the uncertainty in the input parameters. As no licensed HSV vaccine currently 
exists, sensitivity and uncertainty analyses can be useful to delineate the range of possible impacts 
for the business case and to define PPCs under different conditions, determining in which context 
HSV vaccines can be most and least useful. For example, what level of vaccine efficacy against 
infection is required to have an acceptable population impact and cost-effectiveness in different 
settings? Meeting participants agreed it would be important to conduct these types of threshold 
analyses, which can be refined and narrowed as better data become available for different 
parameters. In addition to varying vaccine efficacy, sensitivity and uncertainty analyses can explore 
the impact of varying vaccine uptake, duration of vaccine protection, vaccine costs, and other 
parameters. 
Cost analyses 
None of the published dynamic models of HSV vaccine impact include HSV disease costs, nor the 
relative cost-benefit of a vaccine were one available. Meeting participants agreed that in the future, 
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cost-effectiveness analyses will be needed to incentivize product development, alongside estimates 
of the costs of vaccine research and development. These analyses can also shed light on the time to 
return on investment for different price scenarios, and can guide strategic decision-making and 
policy once a vaccine becomes available. In the simplest format, costs per infection and outcome can 
be applied to predicted number of infections and disease outcomes averted with a vaccine.43 More 
detailed cost-effectiveness models can incorporate the role of alternative interventions, not just for 
HSV treatment (e.g., suppressive therapy) but also for prevention and treatment of HSV-associated 
outcomes (e.g., antiretroviral therapy for HIV infection), and should include the operational costs of 
the vaccine and its delivery in different settings.42  
Conclusions  
Participants in the WHO Consultation on HSV Vaccine Impact Modelling identified several critical 
modelling and data needs to inform development of a comprehensive business case and PPCs for an 
HSV vaccine. The business case will be driven by the estimated burden of HSV infection and disease 
and associated costs. Good global and regional estimates exist for HSV-2 and HSV-1 infection, but 
more work is needed in estimating disease outcomes of HSV infection. To do this, better primary 
data are needed on neonatal herpes incidence and mother-to-child transmission risks in LMICs, and 
existing models of the fraction of HIV infection attributable to HSV-2 can be updated and adapted to 
different settings and epidemic stages. Assessment of HSV-1 infection outcomes will help define the 
full scope of HSV-associated disease. Robust QALY/DALY estimates incorporating the full impact of 
HSV infection on health and well-being are also needed.  Several cost estimates and itemized cost 
components are available in HICs, but similar estimates for LMICs are essential, as is inclusion of 
costs related to neonatal herpes and HIV infection. Better data on healthcare and treatment 
utilization related to HSV and its outcomes will improve cost modelling for all settings. Given wide-
ranging data needs, “expected value of information” analyses can assist in strategizing about which 
data to collect most urgently to inform vaccine impact modelling and the business case.54,55 These 
types of modelling analyses help quantify the added value of a decision made with perfect versus 
imperfect information for different parameters, which can help prioritise the parameters and the 
studies to refine them. 
In order to optimally assess the theoretical population impact of an HSV vaccine, meeting 
participants concluded that new dynamic modelling efforts would be valuable in varied settings 
according to HSV and HIV epidemiology and country-income status, for both prophylactic and 
therapeutic vaccines. Existing dynamic models provide a good foundation for these activities. 
Comparison of model results can provide insight and help reach consensus on the optimal features 
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of new or updated models to inform the HSV vaccine business case and PPCs.52 Meeting participants 
agreed that inclusion of HSV-1 infection in dynamic models, as both an outcome and modifier of 
HSV-2 infection, was crucial, as was inclusion of a broader range of disease outcomes, especially 
neonatal herpes and HIV infection. Sensitivity and uncertainty analyses of the vaccine characteristics 
modelled will be especially important in defining PPCs for HSV vaccines. Finally, meeting participants 
supported incorporation of cost analyses into vaccine impact models to build a coherent business 
case. These activities will advance efforts to develop an efficacious and cost-effective HSV vaccine, a 
critical goal for global public health.  
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Table 1: Key gaps to be addressed related to modelling of HSV burden  
 
Burden of: Summary of existing or 
planned models/estimates 
Major gaps/ new modelling 
efforts needed 
Key new data needs Important considerations 
 
 
HSV-2 infection 
 
• Overall good global estimates; 
sparse data for some regions 
• Global and regional estimates of 
HSV-2 infection for 2012 (WHO) 
• Global Burden of Disease (GBD) 
Study 2013 estimates  
• Comparison of differences 
between WHO/GBD estimates to 
understand underlying 
methods/assumptions 
• Incorporate HSV-2 data from 
high-risk groups to strengthen 
WHO estimates, as in GBD study 
• Update models as new/better 
data become available 
• Nationally-representative 
surveys ideal but not realistic 
• Explore existing but 
unpublished HSV-2 serologic 
data from HIV prevention trials, 
other studies 
• Clarify methods for using high-
risk data to inform general 
population estimates for HSV-2 
• Current estimates generally 
sufficient to inform business 
case 
 
HSV-1 infection 
 
 
• First global and regional HSV-1 
estimates (for 2012) published 
in 2015, for HSV-1 infection 
overall and HSV-1 genital 
infection 
• Data sparse, and more limited 
overall than for HSV-2 
• Update models as new/better 
data become available 
• New serological data to inform 
estimates, especially in  certain 
LIMCs would be valuable  
• Better data on the proportion of 
new HSV-1 infections that are 
genital, including outside the US 
• Better understanding of local 
immunity and interaction 
between HSV types with genital 
HSV-1 
• Current estimates generally 
sufficient to inform business 
case 
 
Genital ulcer disease 
 
 
• No identified comprehensive 
modelled estimates 
• Rough estimate obtained by 
applying simple proportion ever 
symptomatic to global HSV-2 
numbers 
• Model of global and regional 
HSV-related GUD needed 
• Incorporate both HSV-2 and 
HSV-1 and natural history 
• Triangulate from 2 scenarios: 
working forward from global 
HSV infection estimates, and 
backward from surveillance of 
GUD and proportion HSV-
related in different settings 
• Analysis of data from DHS 
surveys: 75 countries doing GUD 
surveillance 
• Systematic review of etiologies 
of GUD in different settings 
• New studies of GUD etiology 
studies and proportion seeking 
care for GUD  
• Better data on natural history of 
genital HSV-1 
• Better data on proportion of 
genital HSV with symptoms in 
different settings and summary 
review/synthesis 
• Need to incorporate increases in 
GUD with HIV infection for high 
HIV-prevalence areas 
• Disease estimates built upon 
infection estimates add 
uncertainty on top of 
uncertainty 
 
 
Neonatal herpes 
 
• First global and regional 
neonatal herpes estimates 
published in 2017  
• Update models as new/better 
data become available 
• Better primary data on neonatal 
herpes incidence is critical, 
especially in LMICs 
• Current estimates a good 
starting point to inform business 
case, but better data needed 
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 • GBD study does not currently 
include neonatal herpes as HSV 
outcome  
• Explore surveillance/research 
networks evaluating neonatal 
deaths, infections and other 
outcomes to include HSV testing 
• Better data on proportion of 
pregnant women shedding HSV 
during labor and transmission 
risks in different settings 
• Better data on proportion of 
pregnant women acquiring new 
HSV infections in late pregnancy  
• Better neonatal herpes numbers 
critical factor in determining 
DALYs for HSV 
• Disease estimates built upon 
infection estimates add 
uncertainty on top of 
uncertainty 
 
 
HSV-related HIV 
infection 
 
 
• Several modelling studies have 
evaluated population 
attributable fraction (PAF) of 
HSV-2 to HIV; good start 
• Published studies limited to 
particular regions/settings 
• GBD study does not currently 
include HSV as risk factor for 
HIV  
• More comprehensive, updated 
models of new HIV infections 
attributable to HSV-2 infections 
• Global and regional estimates, 
considering geographical areas 
with different epidemiologic 
scenarios  
• Work toward including HSV as 
risk factor for HIV in GBD study 
• Updated review and meta-
analysis of the association 
between HSV and HIV infection 
• Better understanding of the risk 
of HIV associated with genital 
HSV-1 infection 
• Epidemiologic scenarios: at least 
high HSV/high HIV prevalence, 
high HSV/low HIV prevalence, 
low HSV/low HIV prevalence 
• Consider early vs mature HIV 
epidemics and where there are 
existing data  
• Add in alternative interventions 
(ARVs, PrEP, etc) to models 
• Published models may not yet 
be sufficient for business case 
 
HSV-1 related oral 
ulcer disease 
 
 
• No identified comprehensive 
modelled estimates 
 
• Estimates of global and regional 
HSV-related oral ulcerative 
disease needed, even if roughly 
apply proportions with 
symptomatic and recurrent 
disase 
 
• Systematic review of the 
occurrence of oral HSV disease 
• Review of the natural history of 
oral HSV-1, including the 
proportion of oral HSV 
infections that are ever 
symptomatic and recurrent 
• Evaluation of administrative or 
claims data on oral HSV-1 
evaluations or treatment 
• Consider dentistry/oral 
medicine literature and 
collaborators 
Other HSV-related 
outcomes: 
Encephalitis, 
keratitis, meningo-
encephalitis, 
disseminated disease, 
etc. 
 
• No identified comprehensive 
modelled estimates that include 
range of HSV-related outcomes 
 
• Summary of best estimates of 
the occurrence of each of the 
more rare outcomes, especially 
encephalitis and keratitis 
• Literature reviews focusing on 
the individual HSV-related 
outcomes 
• Consider the importance of 
immunocompromised 
populations  
Psychosocial impact, • Psychosocial impact (including • Need estimates of quality of life • Expand on pilot studies showing • Most tools focus on symptoms 
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quality of life, quality-
adjusted life years 
(QALYs) 
 
stigma, effect on relationships) 
hard to assess for HSV 
• No identified cost-effectiveness 
studies using QALYs, but several 
good tools exist to estimate 
impact of HSV on quality of life 
• Several estimates of impact of 
neonatal herpes on quality of life 
in HICs 
 
impact of HSV in adults, 
including in LMICs, e.g., lifetime 
QALY loss per case of adult HSV 
• Updated estimates of quality of 
life impact of neonatal herpes, 
including LMICs where possible 
that commonly used quality of 
life metrics yield results 
consistent with the Recurrent 
Genital Herpes Quality of Life 
(RGHQoL) scale 
• Clarify and get consensus on  
definitions to derive QALY 
estimates using existing tools 
• Get quality of life data using 
RGHQoL and other tools in 
LMICs 
 
and daily functioning; more 
difficult to capture effects of 
stigma, effect on current and 
future relationships, etc. 
Years lived with 
disability (YLDs) and 
disability-adjusted 
life years (DALYs) 
 
• YLDs/DALYs for HSV included in 
GBD 2013; however, YLD 
estimates do not currently 
include neonatal herpes and 
HSV-related HIV infection  
• No other identified models 
include YLDs/DALYs as 
outcomes 
 
• Work toward adding HSV-
related HIV infection and 
neonatal herpes in YLD/DALY 
calculations for HSV in GBD 
• Add genital herpes to GBD 
Disability Weights Survey 
• Cross-sectional surveys of those 
with initial/recurrent infection 
with SF-12 or WHODAS-2 
another option to quantify 
health loss 
• Clarify methods to determine 
DALYs across groups 
 
• Better neonatal herpes numbers 
critical factor in determining 
DALYs for HSV 
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Table 2: Key gaps to be addressed related to modelling of HSV costs  
Costs: Summary of existing or 
planned models/estimates 
Major gaps/ new modelling 
efforts needed 
Key new data needs Important considerations 
 
 
HSV-2 infection 
 
• A few national estimates of 
direct annual costs of diagnosing 
and treating HSV-2 exist for US 
• Lifetime cost-per-case estimate 
in US (for diagnosis/treatment) 
• One estimate of indirect costs 
• Main estimates do not include 
costs of neonatal herpes nor 
HSV-associated HIV and use 
older cost data (2000 or before) 
• No aggregate annual cost nor 
lifetime cost-per-case estimates 
found for other countries 
• Many itemized cost components 
available in HICs, e.g., for HSV 
testing, counseling, suppressive 
therapy, clinician visits  
 
• Estimates of costs, both 
aggregate annual and lifetime 
cost-per-case, outside the US, 
especially LMICs 
• Cost estimates that incorporate 
neonatal herpes and HSV-
associated HIV infection 
• Updated cost estimates, using 
current data on HSV testing, 
antiviral use, other measures 
• Review of HSV care and 
treatment costs, especially in 
LMICs  
• Review of care-seeking, health 
care utilization, testing practices 
in different settings for HSV 
disease, especially in LMICs  
• Utilization rates of episodic and 
chronic suppressive therapy for 
HSV in HICs and LMICs 
• Use of multiple data sources, 
including administrative or 
claims data, where possible 
• Explore validated healthcare 
costs in LMICs for similar 
conditions 
• Consider time frame, horizon of 
analysis 
• For LMICs, consider costs that 
would be incurred if national 
recommendations followed; 
treatment may not be used 
because too expensive, but 
vaccine may have relatively 
lower costs to provide standard 
of care 
 
HSV-1 infection 
• No identified comprehensive 
cost estimates  
 
• Estimates of costs, aggregate 
annual and lifetime cost-per-
case, in both HICs and LMICs 
• Incorporation of current data on 
utilization of care and treatment 
for HSV-1-related outcomes 
 
• Better information on HSV-1 
disease occurrence and natural 
history (see Table 1 above) 
• Evaluation of administrative or 
claims data on oral HSV-1 
evaluations and treatment 
• Review oral HSV treatment and 
administration costs (if different 
than genital HSV costs above, 
e.g., topical treatment or over 
the counter medications) 
 
• Consider dentistry/oral 
medicine literature and 
collaborators 
 
Neonatal herpes 
 
 
• Estimates of lifetime cost per 
case of neonatal herpes 
available for US, but not other 
countries 
• Estimates vary substantially 
based on whether long-term 
• Aggregate annual and lifetime 
HSV cost-per-case estimates that 
include neonatal herpes costs 
• Lifetime cost-per-case estimates 
for neonatal herpes outside the 
US, especially LMICs 
• Better data on risks of neonatal 
HSV transmission and neonatal 
herpes incidence in LMICs (see 
Table 1) 
• Neonatal HSV testing, treatment 
methods and rates, and other 
• Consider costs of neonatal 
herpes prevention, including 
serological testing, suppressive 
therapy, and Caesarean sections 
• Use of multiple data sources, 
including administrative or 
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disability costs included  
• Neonatal herpes costs not 
systematically included in US 
aggregate annual cost estimates  
• Several studies of cost-
effectiveness of HSV screening 
and suppressive therapy in 
pregnant women 
• Many itemized cost components 
available in HICs, including 
acute neonatal herpes 
hospitalization costs 
 
• Update neonatal herpes cost 
estimates using current data on 
costs, clinical practice, and long-
term disability, as well as 
indirect costs  
healthcare costs in different 
settings 
• Better data on long-term 
outcomes and associated 
disability costs in all settings 
claims data, where possible 
 
HSV-related HIV 
infection 
 
 
• No specific models of costs 
pertaining to HSV-related HIV 
infection, but several models of 
estimated HIV costs 
• Aggregate annual and lifetime 
HSV cost-per-case estimates that 
include HSV-related HIV 
infection costs 
 
• Updated models of the 
attributable fraction of HIV due 
to HSV infection (see Table 1) 
• Review of existing cost 
estimates for HIV infection 
• Consider effect of HSV-HIV co-
infection on the natural histories 
of each, and associated costs 
(e.g., worsening genital ulcer 
disease, clinical progression of 
HIV, etc.) 
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Product development 
plan and costs 
• What are the steps, and 
timelines to develop 
and approve the vaccine 
in the launch countries?  
• What are the costs? 
• What is the risk / 
probability of success? 
 
Product introduction 
plan and costs 
• How much vaccine is 
needed to support the 
market? 
• What is the cost of 
goods for the vaccine at 
the projected scale?  
 
WHO preferred product  
characteristics (PPCs) 
Defines WHO preferences 
specifically for LMICs, e.g.:  
• Efficacy / safety 
• Infection or disease target 
• Duration of protection 
• Target age / population  
• Immunization strategy 
 
Target product profile (TPP) 
Defines developer’s preferences 
for the global market 
Includes same type of criteria as 
defined in the PPCs, plus: 
• Formulation 
• Presentation 
• Stability 
 
 Return on investment 
Projects revenue in launch 
countries vs development/ 
implementation costs 
Typically includes both HICs  
and LMICs 
 
 
Epidemiology  
How much disease is  
there, and where is it? 
 
Cost burden 
How much does the  
disease cost society? 
Burden of disease 
 
 
Vaccine impact 
modelling  
• How much disease 
would be prevented? 
• How much cost would be 
averted? 
i.e., cost effectiveness  
Considering: 
• PPC/TPP elements 
• Vaccine price 
• Implementation costs 
• Coverage 
 
Market demand 
• What is the market in 
different regions? 
• What is the pricing 
structure? 
• What is the forecasted 
demand and revenue?  
 
Competitive landscape 
• What other non-vaccine 
interventions are available? 
• What other vaccines are in 
development?  
• When will they launch? How is 
this candidate different? 
 
Figure 1. Elements of the comprehensive business case. Elements which are informed by modelling and discussed in this paper are outlined in red. 
The characteristics as defined within the TPP may be the same as those within the PPCs if the vaccine is predominantly targeted to low- and middle-income countries 
(LMICs). However, TPPs typically also consider high-income country (HIC) markets, so characteristics defined within a TPP may differ from those within WHO PPCs. 
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